Organization | Zymeworks Inc.

Zymeworks Inc. Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Vancouver BC Canada (2004)

Organization Overview

First Clinical Trial

2016

NCT02892123

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Zymeworks Inc.

Active Ingredients

Drugs in Phase 3 Trials (9)

Key: Zymeworks Inc. (7) Acquired (2)

capecitabine (xeloda) (2 trials)

cisplatin (platinol) (2 trials)

ctx-009 (2 trials)

fluorouracil (efudex) (2 trials)

oxaliplatin (eloxatin) (2 trials)

paclitaxel (taxol) (1 trial)

tislelizumab (1 trial)

trastuzumab (herceptin) (1 trial)

zw25 (9 trials)

Drugs in Phase 2 Trials (6)

alx148 (1 trial)

fulvestrant (faslodex) (1 trial)

letrozole (femara) (1 trial)

leucovorin (1 trial)

palbociclib (ibrance) (1 trial)

tamoxifen (nolvadex) (1 trial)

Drugs in Phase 1 Trials (3)

Key: Zymeworks Inc. (1) Acquired (2)

ctx-471 (1 trial)

ctx-8371 (1 trial)

zw49 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Biliary Tract Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinosarcoma (Phase 2)

Endometrial Neoplasms (Phase 2)

Mixed Tumor, Mullerian (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 14
# of Trial APIs: 18